KR102464342B1 - 화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도 - Google Patents

화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도 Download PDF

Info

Publication number
KR102464342B1
KR102464342B1 KR1020167016068A KR20167016068A KR102464342B1 KR 102464342 B1 KR102464342 B1 KR 102464342B1 KR 1020167016068 A KR1020167016068 A KR 1020167016068A KR 20167016068 A KR20167016068 A KR 20167016068A KR 102464342 B1 KR102464342 B1 KR 102464342B1
Authority
KR
South Korea
Prior art keywords
ctx
cells
mice
delete delete
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167016068A
Other languages
English (en)
Korean (ko)
Other versions
KR20160079122A (ko
Inventor
로랑스 지포겔
이보 콤퍼츠 보네카
패트리샤 르파주
소피 비오드
로메인 다일레르
Original Assignee
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)
엥스티튀 나쇼날 드 르쉐르슈 푸흐 라그리컬튀흐, 랄리망따씨옹 에 랑비허른망
유니베르시떼 파리-싸끌레
인스티튜트 구스타브 루시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸), 엥스티튀 나쇼날 드 르쉐르슈 푸흐 라그리컬튀흐, 랄리망따씨옹 에 랑비허른망, 유니베르시떼 파리-싸끌레, 인스티튜트 구스타브 루시 filed Critical 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)
Publication of KR20160079122A publication Critical patent/KR20160079122A/ko
Application granted granted Critical
Publication of KR102464342B1 publication Critical patent/KR102464342B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020167016068A 2013-11-21 2014-11-21 화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도 Active KR102464342B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907076P 2013-11-21 2013-11-21
EP13306597.9 2013-11-21
EP13306597.9A EP2876167A1 (en) 2013-11-21 2013-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US61/907,076 2013-11-21
PCT/IB2014/066249 WO2015075688A1 (en) 2013-11-21 2014-11-21 Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment

Publications (2)

Publication Number Publication Date
KR20160079122A KR20160079122A (ko) 2016-07-05
KR102464342B1 true KR102464342B1 (ko) 2022-11-08

Family

ID=49680948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167016068A Active KR102464342B1 (ko) 2013-11-21 2014-11-21 화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도

Country Status (13)

Country Link
US (2) US10646521B2 (enExample)
EP (2) EP2876167A1 (enExample)
JP (2) JP6662775B2 (enExample)
KR (1) KR102464342B1 (enExample)
CN (1) CN106170557B (enExample)
AU (1) AU2014351348B2 (enExample)
CA (1) CA2931363C (enExample)
DK (1) DK3071709T3 (enExample)
ES (1) ES2764282T3 (enExample)
IL (2) IL245751B (enExample)
PT (1) PT3071709T (enExample)
SG (1) SG10201803877YA (enExample)
WO (1) WO2015075688A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112016002056T5 (de) 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
KR102661603B1 (ko) * 2015-06-01 2024-04-29 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
EP3130680A1 (en) * 2015-08-11 2017-02-15 Universitat de Girona Method for the detection, follow up and/or classification of intestinal diseases
EP4592391A3 (en) 2015-10-21 2025-10-08 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
MA45287A (fr) * 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201609811D0 (en) * 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN106011281B (zh) * 2016-07-19 2019-04-23 浙江大学 肠道分节丝状菌鞭毛蛋白的检测方法
CN109715059A (zh) * 2016-09-16 2019-05-03 优比欧迈公司 用于组表征的方法和系统
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
KR102644935B1 (ko) * 2016-12-22 2024-03-07 인스티튜트 구스타브 루시 항-PD1/PD-L1/PD-L2 항체에 대한 반응성의 마커로서의 미생물총 조성물, 및 항-PD1/PD-L1/PD-L2 Ab-기반 치료의 효능을 개선하기 위한 미생물 조정제의 용도
WO2018145082A1 (en) * 2017-02-06 2018-08-09 New York University Methods and compositions for treating and diagnosing pancreatic cancers
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
MA49982A (fr) * 2017-08-10 2020-06-17 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
CN107904298A (zh) * 2017-12-29 2018-04-13 苏州普瑞森基因科技有限公司 一种用于分析肠道微生物的试剂盒及其应用
EP3505177A1 (en) * 2017-12-29 2019-07-03 Institut Gustave Roussy Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
CN111886333A (zh) * 2018-02-09 2020-11-03 学校法人庆应义塾 诱导cd8+t细胞的组合物和方法
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
KR20210040997A (ko) * 2018-08-05 2021-04-14 다 볼떼라 항암제 효능의 개선 방법
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP3629023A1 (en) * 2018-09-28 2020-04-01 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
IL311084A (en) * 2018-11-30 2024-04-01 Caris Mpi Inc New generation molecular characterization
CN113166815B (zh) * 2019-02-22 2024-06-11 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CN113906130A (zh) * 2019-03-28 2022-01-07 千实验室株式会社 粪杆菌属微生物及包含其的抗癌组合物
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
EP3965750A4 (en) * 2019-05-08 2023-07-12 Garvan Institute of Medical Research Cancer stratification and treatment based on inhibition of nod-2
KR20220116438A (ko) * 2019-11-01 2022-08-23 유티아이 리미티드 파트너쉽 암 치료를 위한 미생물총 및 대사산물의 힘 활용
WO2021102510A1 (en) * 2019-11-26 2021-06-03 South Australian Health And Medical Research Institute Limited Methods and products for reducing side effects associated with use of immune agonist antibodies
WO2021112918A1 (en) * 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
CN114832088A (zh) * 2022-05-19 2022-08-02 李臻 拉瑞唑来多肽在制备缓解阿霉素心脏毒性药物中的用途
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116287355A (zh) * 2023-05-12 2023-06-23 中国医学科学院北京协和医院 上消化道肿瘤化疗疗效及不良反应的肠道菌群预测模型
CN117237952B (zh) * 2023-11-15 2024-02-09 山东大学 基于免疫地形图的染色病理切片细胞分布标注方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141240A1 (en) 2007-05-11 2008-11-20 Mannatech, Inc. Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
WO2010033424A2 (en) 2008-09-19 2010-03-25 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295631A (ja) 1995-02-27 1996-11-12 Nichinichi Seiyaku Kk 制癌増強剤
JPH1029946A (ja) * 1996-07-15 1998-02-03 Nichinichi Seiyaku Kk 液性免疫回復剤
CA2736774C (en) 2008-09-19 2017-08-22 Institut Curie Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
JP5717116B2 (ja) * 2008-12-22 2015-05-13 学校法人昭和大学 抗原特異的ヒトＴｈ１７細胞を調整する方法
US8828944B2 (en) * 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141240A1 (en) 2007-05-11 2008-11-20 Mannatech, Inc. Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
WO2010033424A2 (en) 2008-09-19 2010-03-25 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INFECTION AND IMMUNITY, 제63권, 제1호, 57-65면(1995)*

Also Published As

Publication number Publication date
CA2931363A1 (en) 2015-05-28
JP2020050664A (ja) 2020-04-02
KR20160079122A (ko) 2016-07-05
AU2014351348B2 (en) 2020-12-03
EP2876167A1 (en) 2015-05-27
US10646521B2 (en) 2020-05-12
CN106170557B (zh) 2020-08-21
IL245751B (en) 2019-08-29
JP6662775B2 (ja) 2020-03-11
EP3071709B1 (en) 2019-12-25
ES2764282T3 (es) 2020-06-02
US20160303172A1 (en) 2016-10-20
IL268526A (en) 2019-09-26
DK3071709T3 (da) 2020-03-16
CA2931363C (en) 2023-07-18
JP2016539119A (ja) 2016-12-15
US11344586B2 (en) 2022-05-31
PT3071709T (pt) 2020-01-17
CN106170557A (zh) 2016-11-30
IL268526B (en) 2022-02-01
SG10201803877YA (en) 2018-06-28
EP3071709A1 (en) 2016-09-28
WO2015075688A1 (en) 2015-05-28
AU2014351348A1 (en) 2016-06-09
IL245751A0 (en) 2016-07-31
US20200360449A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
KR102464342B1 (ko) 화학요법에 대한 반응성의 마커로서의 미생물총 조성물, 및 암 치료의 효능을 개선하기 위한 미생물 조정제 (프리-, 프로- 또는 신바이오틱스)의 용도
US12144839B2 (en) Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment
Roberti et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer
AU2015334468B2 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
KR102711178B1 (ko) 결장직장암의 치료를 위한 박테리아 및 세포 조성물, 및 이를 갖는 환자의 예후를 평가하는 방법
US20240398876A1 (en) Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-pdi drug
EP2603230A1 (en) Use of blood group status

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190927

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210319

Patent event code: PE09021S01D

AMND Amendment
PN2301 Change of applicant

Patent event date: 20210716

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211014

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210319

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211014

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210518

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190927

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220214

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220901

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220812

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220113

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211014

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210518

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190927

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221102

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration